NDA 021747 · Boehringer Ingelheim
Combivent Respimat
Albuterol Sulfate, Ipratropium Bromide · Inhalation
Last checked: Nov 20, 2026Latest source record: Sep 27, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Oct 7, 2011
Approved uses
1
Original approval plus efficacy supplements
Registered trials
793
238 Phase 3, 24 recruiting
FAERS reports
2,765
1,506 serious, 214 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 1, 2025.
COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. COMBIVENT RESPIMAT Inhalation Spray is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 ‑adrenergic agonist) indicated for: Patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator (1)
Mechanism: COMBIVENT RESPIMAT: COMBIVENT RESPIMAT is a combination of the anticholinergic ipratropium bromide and the beta 2 -adrenergic agonist albuterol sulfate. The mechanisms of action described below for the individual components apply to COMBIVENT RESPIMAT. The two classes of medications (an anticholinergic and a beta 2 -adrenergic agonist) are both bronchodilators. Simultaneous administration of both an anticholinergic (ipratropium bromide) and a beta 2 -sympathomimetic (albuterol sulfate) is designed to produce a greater bronchodilator effect than when either drug is utilized alone at its...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 7, 2011 Original approval · Type 3 - New Dosage Form ReviewLabelSummary Review
1 products under this application
- COMBIVENT RESPIMAT · ALBUTEROL SULFATE EQ 0.1MG BASE/INH; IPRATROPIUM BROMIDE 0.02MG/INH · SPRAY, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Albuterol" as an intervention, any sponsor and status, largest first.
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- A Serious Asthma Outcome Study With Mometasone Furoate/Formoterol Versus Mometasone Furoate in Asthmatics 12 Years and Over (P06241)Pivotal-lookingCompleted
Organon and CoIndustry
NCT01471340 · 11,744 participants · Start Jan 9, 2012 · Primary completion Nov 30, 2016
Drug: Mometasone Furoate/Formoterol MDI 100/5 mcg; Mometasone Furoate/Formoterol MDI 200/5 mcg and 4 more · For: Asthma
- Tiotropium Once Daily 18 Mcg Versus Salmeterol Twice Daily 50 Mcg on Time to First Exacerbation in COPD Patients.Pivotal-lookingCompleted
Boehringer IngelheimBoehringer Ingelheim
NCT00563381 · 7,376 participants · Start Jan 2008 · Primary completion Apr 2010
Drug: Tiotropium bromide; Salmeterol and 2 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Feldbach, Austria; Feldkirch, Austria; Gänserndorf, Austria · 752 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- Individualizing Treatment for Asthma in Primary Care (Full Study)Pivotal-lookingRecruiting
DARTNet InstituteGovernment (non-federal)
NCT07052942 · 3,200 participants (planned) · Start Aug 1, 2025 · Primary completion Nov 15, 2029
Drug: Inhaled corticosteroid (ICS); Azithromycin · For: Asthma; Asthma Attack; Asthma Exacerbations
Sites: Aurora, Colorado; Orlando, Florida; Kansas City, Kansas · 13 sites in all
- A Study to Assess the Efficacy and Safety of Budesonide/Albuterol Metered-dose Inhaler (BDA MDI/PT027) in Adults and Children 4 Years of Age or Older With AsthmaPivotal-lookingCompleted
Bond Avillion 2 Development LPIndustry
NCT03769090 · 3,132 participants · Start Dec 13, 2018 · Primary completion Aug 19, 2021
Drug: Albuterol sulfate metered-dose inhaler 180 μg · For: Asthma
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 345 sites in all
- Study to Compare the Efficacy and Safety of QVM149 With QMF149 in Patients With AsthmaPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02571777 · 3,092 participants · Start Dec 8, 2015 · Primary completion Jun 14, 2019
Drug: QVM149 150/50/160; QVM149 150/50/80 and 3 more · For: Asthma
Sites: Bahía Blanca, Argentina; CABA, Argentina; Florida, Argentina · 403 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea449
- off label use232
- pneumonia195
- drug ineffective171
- fatigue170
- cough168
- headache151
- death133
- nausea132
- pain121
- asthma119
- diarrhoea112
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2011 | 4 |
| 2012 | 6 |
| 2013 | 40 |
| 2014 | 89 |
| 2015 | 151 |
| 2016 | 216 |
| 2017 | 176 |
| 2018 | 225 |
| 2019 | 183 |
| 2020 | 236 |
| 2021 | 178 |
| 2022 | 283 |
| 2023 | 220 |
| 2024 | 276 |
| 2025 | 267 |
| 2026 | 215 |
Recalls
1 FDA enforcement reports for this application.
Jul 24, 2015 · Class II · Terminated
Defective Delivery System: Inhalers do not spray properly, emitting either no spray or a short transient spray.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Combivent Respimat (Ipratropium/Albuterol Sulfate)
2024 spending
$388M
Beneficiaries
154,264
602,035 claims
Per beneficiary
$2,515
$121.11 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $546,288,280 |
| 2021 | $520,262,761 |
| 2022 | $484,615,822 |
| 2023 | $456,397,647 |
| 2024 | $387,905,151 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- As-Needed Albuterol-Budesonide in Mild Asthma.
LaForce C, Albers F, Danilewicz A, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Multicenter Study
- Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Papi A, Chipps BE, Beasley R, et al. · N Engl J Med 2022 · Clinical Trial, Phase III, Comparative Study
- Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Albuterol-Budesonide Pressurized Metered Dose Inhaler in Patients With Mild-to-Moderate Asthma: Results of the DENALI Double-Blind Randomized Controlled Trial.
Chipps BE, Israel E, Beasley R, et al. · Chest 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Albuterol/budesonide for the treatment of exercise-induced bronchoconstriction in patients with asthma: The TYREE study.
LaForce C, Chipps BE, Albers FC, et al. · Ann Allergy Asthma Immunol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis.
Jat KR, Khairwa A · Pulm Pharmacol Ther 2013 · Comparative Study, Meta-Analysis
Sponsor: Boehringer Ingelheim
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.